MSOSAdvisorShares Pure US Cannabis ETF
Seeks long-term capital appreciation.
By AdvisorShares · Launched 2020
Annual Cost
0.78%
#4,083 of 5,854 · expensive
Fund Size
$1.0B
#1,103 of 5,854 · large
Return (1Y)Goal
+43.4%
Track Record
5 years
#2,126 of 5,854 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$14,947+49.5%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundWhat it actually holds
By weightConcentration
Top 2 holdings = 21.6% of fund✓ well diversified
Curaleaf Holdings IncCURA.TO
12.2%
Trulieve Cannabis Corp Ordinary Shares (Sub Voting)TRLV
9.4%
Asset allocation
Cash
63.8%
Stocks
29.1%
Other
7.1%
By sector
Real Estate
50.2%
Industrials
29.6%
Consumer Cyclical
17.8%
Healthcare
2.5%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
111.2%High
Year-on-year price swings
Max drawdown
-96.2%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.32Below average
Sortino (3Y)
0.52Moderate downside risk
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks long-term capital appreciation.
- Strategy
- Actively manages a portfolio primarily invested in mid- and small-cap U.S. companies deriving at least 50% of revenue from the marijuana and hemp business. Concentrates at least 25% in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector.
- Inception date
- September 1, 2020
- Fund family
- AdvisorShares
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at MSOS. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-04